These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 1698165)
1. Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides. Lang AB; Fürer E; Schürch U; Cross AS; Larrick JW; Cryz SJ Dev Biol Stand; 1990; 71():121-6. PubMed ID: 1698165 [TBL] [Abstract][Full Text] [Related]
2. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibodies specific for capsular polysaccharides of Klebsiella recognize clusters of multiple serotypes. Lang AB; Bruderer U; Senyk G; Pitt TL; Larrick JW; Cryz SJ J Immunol; 1991 May; 146(9):3160-4. PubMed ID: 2016541 [TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides. Lang AB; Fürer E; Larrick JW; Cryz SJ Infect Immun; 1989 Dec; 57(12):3851-5. PubMed ID: 2509371 [TBL] [Abstract][Full Text] [Related]
5. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231 [TBL] [Abstract][Full Text] [Related]
6. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215 [TBL] [Abstract][Full Text] [Related]
8. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the human immune response to a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Cryz SJ; Sadoff JC; Ohman D; Fürer E J Lab Clin Med; 1988 Jun; 111(6):701-7. PubMed ID: 3131471 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients. Lang AB; Horn MP; Imboden MA; Zuercher AW Vaccine; 2004 Dec; 22 Suppl 1():S44-8. PubMed ID: 15576201 [TBL] [Abstract][Full Text] [Related]
11. Production of anti-tumor human monoclonal antibodies using different approaches. Liu H; Xu ZL; Wang Y; Yang L; Feng O; Li Y; Wang YM; Zhang GG Hum Antibodies Hybridomas; 1993 Jan; 4(1):2-8. PubMed ID: 8381684 [TBL] [Abstract][Full Text] [Related]
12. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium, Pseudomonas aeruginosa. Markham RB; Pier GB; Schreiber JR J Immunol; 1991 Jan; 146(1):316-20. PubMed ID: 1898604 [TBL] [Abstract][Full Text] [Related]
13. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. Collins MS; Ladehoff DK; Mehton NS; Noonan JS FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368 [TBL] [Abstract][Full Text] [Related]
14. Production and partial characterization of monoclonal antibodies to Pasteurella haemolytica A1 capsular polysaccharide and lipopolysaccharide. Penaredondo MV; Maheswaran SK; Whiteley LO; Ames TR; Leininger JR Am J Vet Res; 1988 Nov; 49(11):1962-8. PubMed ID: 2470277 [TBL] [Abstract][Full Text] [Related]
15. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845 [TBL] [Abstract][Full Text] [Related]
17. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. Pollack M; Huang AI; Prescott RK; Young LS; Hunter KW; Cruess DF; Tsai CM J Clin Invest; 1983 Dec; 72(6):1874-81. PubMed ID: 6358257 [TBL] [Abstract][Full Text] [Related]
18. Polysaccharide antigens of Pseudomonas aeruginosa. Knirel YA Crit Rev Microbiol; 1990; 17(4):273-304. PubMed ID: 1698385 [TBL] [Abstract][Full Text] [Related]
19. Generation and characterization of a human monoclonal IgM antibody that recognizes a conserved epitope shared by lipopolysaccharides of different gram-negative bacteria. Seifert M; Schoenherr G; Roggenbuck D; Marx U; von Baehr R Hybridoma; 1996 Jun; 15(3):191-8. PubMed ID: 8823616 [TBL] [Abstract][Full Text] [Related]